The current socioeconomic and regulatory landscape of immune effector cell therapies
C Sainatham, D Yadav, A Dilli Babu… - Frontiers in …, 2024 - frontiersin.org
Immune cell effector therapies, including chimeric antigen receptor (CAR)-T cells, T-cell
receptor (TCR) T cells, natural killer (NK) cells, and macrophage-based therapies, represent …
receptor (TCR) T cells, natural killer (NK) cells, and macrophage-based therapies, represent …
Role of Clinical Pharmacology in Diversity and Inclusion in Global Drug Development: Current Practices and Industry Perspectives: White Paper
A Sawant‐Basak, S Urva, JK Mukker… - Clinical …, 2024 - Wiley Online Library
The 2022 United States Food and Drug Administration (US FDA) draft guidance on diversity
plan (DP), which will be implemented through the Diversity Action Plans by December 2025 …
plan (DP), which will be implemented through the Diversity Action Plans by December 2025 …
Disparities in Clinical Trial Enrollment–Focus on CAR-T and Bispecific Antibody Therapies
N Islam, L Budvytyte, N Khera, T Hilal - Current Hematologic Malignancy …, 2025 - Springer
Disparities in Clinical Trial Enrollment– Focus on CAR-T and Bispecific Antibody Therapies |
Current Hematologic Malignancy Reports Skip to main content Springer Nature Link Account …
Current Hematologic Malignancy Reports Skip to main content Springer Nature Link Account …
Race and insurance: real-world insights on CAR-T outcomes
N Ahmed, NS Grover - Blood Advances, 2024 - ashpublications.org
In this issue of Blood Advances, Karmali et al 1 identified the impact of racial and insurance
disparities on survival outcomes in patients with diffuse large B-cell lymphoma …
disparities on survival outcomes in patients with diffuse large B-cell lymphoma …
Mitigating time toxicity in lymphoma and multiple myeloma
The concept of time toxicity in oncology refers to the presence of frequent healthcare-related
interactions that can interfere with patient well-being. In this review, we examine several …
interactions that can interfere with patient well-being. In this review, we examine several …
Association of age, race, and ethnicity with access, response, and toxicities from CAR-T therapy in children and adults with B-cell malignancies: a review
G Ghilardi, ZS Hasanali… - … for ImmunoTherapy of …, 2025 - jitc.bmj.com
Chimeric antigen receptor T cell (CAR-T) therapies are now standard-of-care for several B-
cell malignancies, and additional indications are being evaluated. In this review, we survey …
cell malignancies, and additional indications are being evaluated. In this review, we survey …
Axi-cel outcomes among non-Hispanic Black patients
W Wesson, N Ahmed - Blood, 2024 - ashpublications.org
In this issue of Blood, Locke et al describe the safety and efficacy outcomes of axicabtagene
ciloleucel (axi-cel) across racial and ethnic groups. 1 Their study included 1,290 patients in …
ciloleucel (axi-cel) across racial and ethnic groups. 1 Their study included 1,290 patients in …
Dampening Logistics Creating Inequitable Access: A Major Threat Despite Advancements
FS Ayoobkhan, AO Abdallah… - Clinical …, 2024 - clinical-lymphoma-myeloma …
We read with great interest the recent publication by Shahzad et al. titled “Geographic and
Racial Disparities in Chimeric Antigen Receptor–T Cells and Bi-specific Antibodies Trials …
Racial Disparities in Chimeric Antigen Receptor–T Cells and Bi-specific Antibodies Trials …